

**Date and Time:** 10.00am – 16.00pm – 15<sup>th</sup> October 2013

**Minutes:** confirmed

**Guideline Development Group Meeting Tuberculosis**

**Place:** *Spring Gardens,  
NICE Offices,  
London*

**Present:** Andrew Hayward (AH) (Chair)  
Ibrahim Abubakar (IA)  
Christine Bell (CB)  
Ann Chapman (AC)  
Timothy Collyns (TC)  
Francis Drobniowski (FD)  
Michael Eisenhut (ME)  
Marc Lipman (ML)  
Tessa Marshall (TM)  
Amy McConville (AM)  
Horace Reid (HR)  
Al Story (AS)  
Bertie Squire (BS)  
John Watson (JW)

**Apologies:** Faizan Ahmed (FA)  
Mango Hoto (MH)  
Toni Tan (TT)

**In attendance:**

NICE Staff:

Emma Banks (EB)  
Chris Cooper (CC)  
Ben Doak (BD)  
Sue Ellerby (SE)  
Chris Gibbons (CG)  
Michael Heath (MH)  
Lucy Hoppe (LH)  
Andrew Hoy (AHoy)  
Lyn Knott (LK)  
Claire McCleod (CM)  
Robby Richey (RR)  
Gabriel Rogers (GR)

---

**Notes**

## Notes

### 15<sup>th</sup> October

1. AH welcomed all to the sixth TB GDG meeting. Apologies were noted and the minutes of the last meeting were agreed as an accurate record of the previous meeting.

The Chair asked all GDG members to declare any new relevant conflicts of interest. All in attendance at the meeting declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline that had not already been declared on appointment to the committee.

The Chair introduced the work to be presented and discussed.

2. AHoy highlighted revisions made, following the last GDG meeting, to the public health review protocol for the review questions on information, education and support.
3. RR presented the evidence for the clinical review questions on the most effective regimen, duration of treatment and the effectiveness of intermittent dosing in people with drug resistant TB. The GDG once again noted that the reporting of studies was poor and the evidence on outcomes was of low quality. The group discussed all the evidence and went on to make draft recommendations.
4. AM shared her experience of dealing with TB from a patient perspective highlighting to the group the impact on her life physically, mentally and financially.
5. LH presented the evidence for the clinical review questions on the effectiveness of surgery in people with drug resistant TB. The group discussed the evidence and made draft recommendations.
6. There were no further matters of business arising so AH thanks all attendees for their input.

### **Date, time and venue of the next meeting**

10am – Monday 9<sup>th</sup> December and Tuesday 10<sup>th</sup> December 2013 – NICE offices, Manchester